key: cord-1018225-ew49kad9
authors: Karapetyan, N.; Danielyan, S.; Safaryan, L.; Harutyunyan, L.; Avagyan, A.; Tamamyan, G.; Arakelyan, T.; Arakelyan, J.; Bardakhcyan, S.; Harutyunyan, M.; Sargsyan, A.; Mailyan, M.; Sargsyan, M.; Rushanyan, M.; Mkrtchyan, G.; Galoyan, A.; Zohrabyan, D.
title: 1579P The risk of severe/critical COVID-19 infection in patients diagnosed with solid malignancies: Two center experience from Armenia
date: 2021-09-30
journal: Annals of Oncology
DOI: 10.1016/j.annonc.2021.08.1572
sha: 26fb19c5b29aa0cbad14af1462114afb5cd97a8f
doc_id: 1018225
cord_uid: ew49kad9

Background: Nowadays, the data on Coronavirus Disease 2019 (COVID-19) among cancer patients is controversial. It is debatable whether cancer patients are at a significantly higher risk of severe COVID-19. The current study aims to assess the risk of severe and critical COVID-19 cases among patients receiving systemic anticancer treatment (SACT). Methods: This was a retrospective cohort study utilizing census sampling. The data was obtained through medical records. Inclusion criteria: COVID-19 diagnosis through RT-PCR/chest CT among those who received SACT in the Chemotherapy Departments of Hematology Center after prof. Yeolyan and Institute of Surgery after Mikaelyan Yerevan, Armenia between March 1, 2020, and February 1, 2021. Descriptive analysis was done to characterize the cohort. We run logistic regression to evaluate the risk of COVID-19 severity (mild, severe/critical) among those receiving SACT (high, intermediate, and low-risk protocols of febrile neutropenia (FN), age, gender, smoking status, comorbidities). Results: In total 75 cancer patients were diagnosed with COVID-19 in both centers. Data of only 72 patients were analyzed, as the outcome variable of the excluded patients was unknown. The male-to-female ratio was 1:1.5, age range was 31-80 years (median age: 61). The patients received SACT with high (13.9 %), intermediate (63.9 %), and low (8.3 %) risk for FN. The others did not receive SACT at the moment of COVID-19 diagnosis. Infection-associated pneumonia was developed in 63% of cases. Mild COVID-19 was diagnosed in 76.4% and severe/critical in 23.6% of cases. Infected patients’ hospitalization rate was 28%. The case fatality rate was 8%. Only patients who underwent SACT at the time of COVID-19 infection were included in logistic regression analysis (n=62). Significant association between COVID-19 severity and the risk of SACT-induced FN, gender, smoking status, comorbidities was not found. Contrary, COVID-19 severity was significantly associated with age when adjusted to other predictors (p=0.017, 95% CI = 1.021-1.230). Conclusions: Thus, we demonstrate the lack of rationale to reschedule SACT during the pandemic as it does not affect the COVID-19 severity and may bring unnecessary treatment delays. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.

respiratory tract malignancies (10%). Most patients were on active systemic therapy or radiotherapy (84%), largely for advanced or metastatic disease (55%). In the overall population, early death rate was 15%, which was numerically higher than the Brazilian general population with COVID-19 diagnosis in 2020 (2.5%). We were able to match 442 cancer patients with COVID-19 to 1,187 controls with cancer from pre-pandemic times. The 30-day mortality rate was 12.4% in COVID-19 cases as compared to 5.4% in pre-pandemic controls with cancer (Odds Ratio 2.49, 95%CI 1.67 -3.70; P value < 0.01, Power 97.5%). COVID-19 cancer patients had significantly higher death events than historical controls (Hazard Ratio 2.18, 95%CI 1.52 -3.12; P value < 0.01, Power 99.7%), particularly from 20 to 30 days after diagnosis of the infection.

Conclusions: Cancer patients with COVID-19 have an excess mortality 30 days after the infection when compared to matched cancer population from pre-pandemic times and the general population with COVID-19, reinforcing the need for priority vaccination in public health strategies.

Legal entity responsible for the study: Oncoclínicas Group.

Funding: Amgen. Conclusions: The outcomes of our cohort of patients with cancer who tested positive for COVID-19 and hospitalised were poor. The high comorbidity burden and poor ECOG PS could potentially account for this rather than the recent oncological treatment. Acute oncology input to general medical teams treating cancer patients with COVID-19 is pivotal for best possible outcomes for patients.

Legal entity responsible for the study: Konstantinos Kamposioras.

Funding: Has not received any funding. Conclusions: Thus, we demonstrate the lack of rationale to reschedule SACT during the pandemic as it does not affect the COVID-19 severity and may bring unnecessary treatment delays.

Legal entity responsible for the study: The authors.

Funding: Has not received any funding. 

Sociedad de Oncologia y Hematologia del Cesar

Methods: ACHOCC-19B registry is a multicenter observational study composed of a cross-sectional and a prospective cohort component. Eligibility criteria were the diagnosis of breast cancer and COVID-19 infection confirmed with RT-PCR. Follow-up of 30 days was completed. Clinical data were extracted of the multicentric register of cancer and covid-19 in Colombia (ACHOCC-19